Comparison · NCT02826603-920c213c
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12. Trial comparisons, record NCT02826603-920c213c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02826603-920c213c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.665 | 0.625 | 0.704 | wilson | |
| Risk in group 2 | 0.48 | 0.439 | 0.522 | wilson | |
| Risk difference, group 1 minus group 2 | 0.185 | 0.127 | 0.242 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.39 | 1.25 | 1.54 | log | |
| Odds ratio, group 1 over group 2 | 2.15 | 1.69 | 2.75 | log | |
| Number needed to treat, for one more participant with the outcome on Secukinumab 300mg (2 x 150 mg) than on Ustekinumab 2 x 45mg or 90mg | 5.39 | 4.14 | 7.86 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Secukinumab 300mg (2 x 150 mg) | Secukinumab 300mg s.c. injection (2 150mg pre-fiilled syringes) | 366 | 550 | OG000 |
| Group 2 | Ustekinumab 2 x 45mg or 90mg | Ustekinumab s.c. 45 mg or 90 mg (depending on body weight) using 45mg pre-filled syringes (1 or 2 syringes) | 265 | 552 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12
- Description
Number of participants who achieved ≥ 90% reduction in PASI compared to baseline.~Logistic regression analysis of PASI 90 response at Week 12~PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, upper limbs, trunk, lower limbs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of body region(head: 0.1, upper limbs: 0.2, trunk: 0.3, lower limbs: 0.4).
- Time frame
- Week 12
- Population
The Full analysis set (FAS) is all patients from the randomized set assigned to study treatment. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned at randomization. If the actual randomization stratum was different to the assigned stratum in IRT, the actual stratum was used in the analyses.
Source ClinicalTrials.gov
Trial
- Title
- Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
- NCT number
- NCT02826603
- Phases
- PHASE3
- Conditions
- Plaque Psoriasis
- Interventions
- Secukinumab, Ustekinumab
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2019-07-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02826603?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02826603-920c213c